Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Eversense® App is a software application that runs on a mobile device (e.g., smartphone or tablet) and displays glucose data in a variety of ways. It also provides alerts based on the glucose settings you choose.
The Eversense® App screens layout will vary based on your mobile device’s model and/or operating system.
Once a new sensor is inserted by your health care professional and paired with the transmitter using the Eversense® App, it will start the 24-hour warm-up phase. Once the 24-hour warm-up phase is completed, you will begin the Initialization Phase.
Initialization Phase (after 24-hour Warm-Up Phase)
During this phase, 4 finger stick blood glucose meter tests are required.
- The 4 calibration tests must be spaced 2 to 12 hours apart, and all 4 tests must be completed within a 36 hour period.
– 1st calibration = 24 hours after sensor insertion.
– 2nd calibration = 2 to 12 hours after 1st successful calibration.
– 3rd calibration = 2 to 12 hours after 2nd successful calibration.
– 4th calibration = 2 to 12 hours after 3rd successful calibration.
- Glucose readings will start displaying in the app a few minutes after the 2nd calibration is successfully completed.
Speak to your health care professional to determine your personal high and low glucose alert levels. Do not change your glucose alert levels without consulting with your health care professional.
The high and low glucose levels in the app are pre-set, but can be customized to your preferences. Based on the preset (default) glucose levels:
“HI” Reading Indicates a sensor glucose reading is greater than 400 mg/dL
“LO” Reading Indicates sensor glucose reading is less than 40 mg/dL
High Alert – 250 mg/dL
Low Alert – 65 mg/dL
High Target – 180 mg/dL
Low Target - 70 mg/dL
The Eversense® App has a “Do Not Disturb” option for non-critical alerts.
Tap Menu > Settings > Sound Settings to display the SOUND SETTINGS screen.
Activating the “Do Not Disturb” option will turn off all non-critical alerts and notifications, and these will not appear and the transmitter will not vibrate for these.
IMPORTANT TO NOTE: Critical alerts cannot be turned off.
Critical alerts include:
- Low Glucose
- Out of range low glucose
- Out of range high glucose
- Battery empty
- Sensor replacement
- High Smart transmitter temperature
- Low sensor temperature
- High sensor temperature
- Smart transmitter error
- Charge Smart Transmitter
- No Sensor Detected
- Transmitter Error
- Vibration Motor
- Transmitter Replacement (Day 396, 395, 366)
- Battery Error
- Sensor File Error
- Incompatible Transmitter
- Data Unavailable
All other alerts and notifications will be suppressed when Do Not Disturb is turned on.
Critical alerts include:
- Low Glucose
- Out of range low glucose
- Out of range high glucose
- Battery empty
- Sensor replacement
- High Smart transmitter temperature
- Low sensor temperature
- High sensor temperature
- Smart transmitter error
- Charge Smart Transmitter
- No Sensor Detected
- Transmitter Error
- Vibration Motor
- Transmitter Replacement (Day 396, 395, 366)
- Battery Error
- Sensor File Error
- Incompatible Transmitter
- Data Unavailable
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060